Advertisement

Journal of Anesthesia

, Volume 32, Issue 5, pp 731–739 | Cite as

Remifentanil suppresses increase in interleukin-6 mRNA in the brain by inhibiting cyclic AMP synthesis

  • Shigeru Maeda
  • Tsugunobu Andoh
  • Rieko Onishi
  • Yumiko Tomoyasu
  • Hitoshi Higuchi
  • Takuya Miyawaki
Original Article
  • 129 Downloads

Abstract

Purpose

Neuronal inflammation is caused by systemic inflammation and induces cognitive dysfunction. IL-6 plays a crucial role in therapies for neuronal inflammation and cognitive dysfunction. Remifentanil, an ultra-short-acting opioid, controls inflammatory reactions in the periphery, but not in the brain. Therefore, the anti-inflammatory effects of remifentanil in neuronal tissue and the involvement of cAMP in these effects were investigated in the present study.

Methods

Mice were divided into 4 groups: control, remifentanil, LPS, and LPS + remifentanil. Brain levels of pro-inflammatory cytokine mRNA, and serum levels of corticosterone, catecholamine and IL-6 were measured in the 4 groups. The co-localization of IL-6 and astrocytes in the mouse brain after the LPS injection was validated by immunostaining. LPS and/or remifentanil-induced changes in intracellular cAMP levels in cultured glial cells were measured, and the effects of cAMP on LPS-induced IL-6 mRNA expression levels were evaluated.

Results

Remifentanil suppressed increase in IL-6 mRNA levels in the mouse brain, and also inhibited the responses of plasma IL-6, corticosterone, and noradrenaline in an inflammatory state. In the hypothalamus, IL-6 was localized in the median eminence, at which GFAP immunoreactivity was specifically detected. In cultured cells, remifentanil suppressed increase in IL-6 mRNA levels and intracellular cAMP levels after the administration of LPS, and this enhanced IL-6 mRNA expression in response to LPS.

Conclusion

Remifentanil suppressed increase in IL-6 mRNA levels in the brain in an inflammatory state, and this effect may be attributed to its direct action on neuronal cells through the inhibition of intracellular cAMP rather than corticosterone.

Keywords

CNS diseases Inflammation Interleukin-6 Remifentanil cAMP 

Notes

Acknowledgements

This work was supported by JSPS KAKENHI Grant Numbers 25463135 and 16K1175008.

Author contributions

SM conducted the in vivo and in vitro studies; SM wrote the manuscript; AT conducted HPLC; RO and YT conducted some of the in vitro analyses; HH developed the models used for the analyses of in vitro data; MT supervised the work and manuscript preparation.

Compliance with ethical standards

Conflict of interest

The authors declare no competing interests.

References

  1. 1.
    Michels M, Steckert AV, Quevedo J, Barichello T, Dal-Pizzol F. Mechanisms of long-term cognitive dysfunction of sepsis: from blood-borne leukocytes to glial cells. Intensive Care Med Exp. 2015;3:30.CrossRefGoogle Scholar
  2. 2.
    Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010;304:1787–94.CrossRefGoogle Scholar
  3. 3.
    Raats JW, van Eijsden WA, Crolla RM, Steyerberg EW, van der Laan L. Risk factors and outcomes for postoperative delirium after major surgery in elderly patients. PLoS One. 2015;10:e0136071.CrossRefGoogle Scholar
  4. 4.
    Rudolph JL, Schreiber KA, Culley DJ, McGlinchey RE, Crosby G, Levitsky S, Marcantonio ER. Measurement of post-operative cognitive dysfunction after cardiac surgery: a systematic review. Acta Anaesthesiol Scand. 2010;54:663–77.CrossRefGoogle Scholar
  5. 5.
    Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol. 2005;4:371–80.CrossRefGoogle Scholar
  6. 6.
    Hovens IB, Schoemaker RG, van der Zee EA, Absalom AR, Heineman E, van Leeuwen BL. Postoperative cognitive dysfunction: Involvement of neuroinflammation and neuronal functioning. Brain Behav Immun. 2014;38:202–10.CrossRefGoogle Scholar
  7. 7.
    Fidalgo AR, Cibelli M, White JP, Nagy I, Maze M, Ma D. Systemic inflammation enhances surgery-induced cognitive dysfunction in mice. Neurosci Lett. 2011;498:63–6.CrossRefGoogle Scholar
  8. 8.
    Kahn MS, Kranjac D, Alonzo CA, Haase JH, Cedillos RO, McLinden KA, Boehm GW, Chumley MJ. Prolonged elevation in hippocampal Abeta and cognitive deficits following repeated endotoxin exposure in the mouse. Behav Brain Res. 2012;229:176–84.CrossRefGoogle Scholar
  9. 9.
    Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci. 2012;8:1254–66.CrossRefGoogle Scholar
  10. 10.
    Capri M, Yani SL, Chattat R, Fortuna D, Bucci L, Lanzarini C, Morsiani C, Catena F, Ansaloni L, Adversi M, Melotti MR, Di Nino G, Franceschi C. Pre-operative, high-IL-6 blood level is a risk factor of post-operative delirium onset in old patients. Front Endocrinol (Lausanne). 2014;5:173.Google Scholar
  11. 11.
    Jiang P, Ling Q, Liu H, Tu W. Intracisternal administration of an interleukin-6 receptor antagonist attenuates surgery-induced cognitive impairment by inhibition of neuroinflammatory responses in aged rats. Exp Ther Med. 2015;9:982–6.CrossRefGoogle Scholar
  12. 12.
    Zongze Z, Jia Z, Chang C, Kai C, Yanlin W. Protective effects of remifentanil on septic mice. Mol Biol Rep. 2010;37:2803–8.CrossRefGoogle Scholar
  13. 13.
    Zhang Y, Du Z, Zhou Q, Wang Y, Li J. Remifentanil attenuates lipopolysaccharide-induced acute lung injury by downregulating the NF-kappaB signaling pathway. Inflammation. 2014;37:1654–60.CrossRefGoogle Scholar
  14. 14.
    Ke JJ, Zhan J, Feng XB, Wu Y, Rao Y, Wang YL. A comparison of the effect of total intravenous anaesthesia with propofol and remifentanil and inhalational anaesthesia with isoflurane on the release of pro- and anti-inflammatory cytokines in patients undergoing open cholecystectomy. Anaesth Intensive Care. 2008;36:74–8.PubMedGoogle Scholar
  15. 15.
    Wu Y, Wang Y, Zhan J. Effects of remifentanyl and fentanyl on LPS-induced cytokine release in human whole blood in vitro. Mol Biol Rep. 2009;36:1113–7.CrossRefGoogle Scholar
  16. 16.
    De Cosmo G, Sessa F, Fiorini F, Congedo E. Effect of remifentanil and fentanyl on postoperative cognitive function and cytokines level in elderly patients undergoing major abdominal surgery. J Clin Anesth. 2016;35:40–6.CrossRefGoogle Scholar
  17. 17.
    Tanabe K, Matsushima-Nishiwaki R, Kozawa O, Iida H. Dexmedetomidine suppresses interleukin-1beta-induced interleukin-6 synthesis in rat glial cells. Int J Mol Med. 2014;34:1032–8.CrossRefGoogle Scholar
  18. 18.
    Wen AY, Sakamoto KM, Miller LS. The role of the transcription factor CREB in immune function. J Immunol. 2010;185:6413–9.CrossRefGoogle Scholar
  19. 19.
    Maeda S, Nakatsuka I, Hayashi Y, Higuchi H, Shimada M, Miyawaki T. Heme oxygenase-1 induction in the brain during lipopolysaccharide-induced acute inflammation. Neuropsychiatr Dis Treat. 2008;4:663–7.CrossRefGoogle Scholar
  20. 20.
    Tonelli LH, Maeda S, Rapp KL, Sternberg EM. Differential induction of interleukin-I beta mRNA in the brain parenchyma of Lewis and Fischer rats after peripheral injection of lipopolysaccharides. J Neuroimmunol. 2003;140:126–36.CrossRefGoogle Scholar
  21. 21.
    Cho SS, Rudloff I, Berger PJ, Irwin MG, Nold MF, Cheng W, Nold-Petry CA. Remifentanil ameliorates intestinal ischemia-reperfusion injury. BMC Gastroenterol. 2013;13:69.CrossRefGoogle Scholar
  22. 22.
    Burkle H, Dunbar S, Van Aken H. Remifentanil: a novel, short-acting, mu-opioid. Anesth Analg. 1996;83:646–51.CrossRefGoogle Scholar
  23. 23.
    Philippe D, Dubuquoy L, Groux H, Brun V, Chuoi-Mariot MT, Gaveriaux-Ruff C, Colombel JF, Kieffer BL, Desreumaux P. Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. J Clin Invest. 2003;111:1329–38.CrossRefGoogle Scholar
  24. 24.
    Zielinska M, Ben Haddou T, Cami-Kobeci G, Salaga M, Jarmuz A, Padysz M, Kordek R, Spetea M, Husbands SM, Fichna J. Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in mice. Eur J Pharmacol. 2015;765:582–90.CrossRefGoogle Scholar
  25. 25.
    Tanabe K, Kozawa O, Iida H. cAMP/PKA enhances interleukin-1beta-induced interleukin-6 synthesis through STAT3 in glial cells. Cell Signal. 2016;28:19–24.CrossRefGoogle Scholar
  26. 26.
    Zumwalt JW, Thunstrom BJ, Spangelo BL. Interleukin-1beta and catecholamines synergistically stimulate interleukin-6 release from rat C6 glioma cells in vitro: a potential role for lysophosphatidylcholine. Endocrinology. 1999;140:888–96.CrossRefGoogle Scholar
  27. 27.
    Tanabe K, Kozawa O, Iida H. Midazolam suppresses interleukin-1beta-induced interleukin-6 release from rat glial cells. J Neuroinflamm. 2011;8:68.CrossRefGoogle Scholar
  28. 28.
    Tasken K, Aandahl EM. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev. 2004;84:137–67.CrossRefGoogle Scholar
  29. 29.
    Zhu T, Wu XL, Zhang W, Xiao M. Glucagon like peptide-1 (GLP-1) modulates OVA-induced airway inflammation and mucus secretion involving a protein kinase A (PKA)-dependent nuclear factor-kappaB (NF-kappaB) signaling pathway in mice. Int J Mol Sci. 2015;16:20195–211.CrossRefGoogle Scholar
  30. 30.
    Gerlo S, Kooijman R, Beck IM, Kolmus K, Spooren A, Haegeman G. Cyclic AMP: a selective modulator of NF-kappaB action. Cell Mol Life Sci. 2011;68:3823–41.CrossRefGoogle Scholar
  31. 31.
    Gao N, Hibi Y, Cueno M, Asamitsu K, Okamoto T. A-kinase-interacting protein 1 (AKIP1) acts as a molecular determinant of PKA in NF-kappaB signaling. J Biol Chem. 2010;285:28097–104.CrossRefGoogle Scholar
  32. 32.
    Sacerdote P. Opioids and the immune system. Palliat Med. 2006;20(Suppl 1):s9–15.PubMedGoogle Scholar
  33. 33.
    Eskandari F, Sternberg EM. Neural-immune interactions in health and disease. Ann N Y Acad Sci. 2002;966:20–7.CrossRefGoogle Scholar
  34. 34.
    Rivest S. Regulation of innate immune responses in the brain. Nat Rev Immunol. 2009;9:429–39.CrossRefGoogle Scholar
  35. 35.
    Han Y, Jiang C, Tang J, Wang C, Wu P, Zhang G, Liu W, Jamangulova N, Wu X, Song X. Resveratrol reduces morphine tolerance by inhibiting microglial activation via AMPK signalling. Eur J Pain. 2014;18:1458–70.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Anesthesiologists 2018

Authors and Affiliations

  1. 1.Department of Dental AnesthesiologyOkayama University HospitalOkayamaJapan
  2. 2.Department of Applied Pharmacology, Graduate School of Medicine and Pharmaceutical SciencesUniversity of ToyamaToyamaJapan
  3. 3.Department of Dental Anesthesiology, and Special Care Dentistry, Okayama University Graduate School of MedicineDentistry and Pharmaceutical SciencesOkayamaJapan

Personalised recommendations